Central nervous system primitive neuro-ectodermal tumors (CNS-PNETs), have recently been reclassified in the most recent 2016 WHO Classification into a standby catch all category, ''CNS Embryonal Tumor, not otherwise specified" (CNS embryonal tumor, NOS) based on epigenetic, biologic and histopathologic criteria. CNS embryonal tumors (NOS) are a rare, histologically and molecularly heterogeneous group of tumors that predominantly affect children, and occasionally adults. Diagnosis of this entity continues to be challenging and the ramifications of misdiagnosis of this aggressive class of brain tumors are significant. We report the case of a 45-year-old woman who was diagnosed with a central nervous system embryonal tumor (NOS) based on immunohistochemical analysis of the patient's tumor at diagnosis. However, later genome-wide methylation profiling of the diagnostic tumor undertaken to guide treatment, revealed characteristics most consistent with IDH-mutant astrocytoma. DNA sequencing and immunohistochemistry confirmed the presence of IDH1 and ATRX mutations resulting in a revised diagnosis of high-grade small cell astrocytoma, and the implementation of a less aggressive treatment regime tailored more appropriately to the patient's tumor type. This case highlights the inadequacy of histology alone for the diagnosis of brain tumours and the utility of methylation profiling and integrated genomic analysis for the diagnostic verification of adults with suspected CNS embryonal tumor (NOS), and is consistent with the increasing realization in the field that a combined diagnostic approach based on clinical, histopathological and molecular data is required to more accurately distinguish brain tumor subtypes and inform more effective therapy.
Introduction
Over the past decade, the omics era has revolutionized our understanding of central nervous system (CNS) tumors and revealed that many of these cancers are heterogeneous and not single disease entities, as first thought. In particular, central nervous system primitive neuro-ectodermal tumors (CNS-PNETs), which were first included as an entity in the 1993s edition of the WHO Classification of CNS tumors under 'medulloblastoma-like, outside of the cerebellum' [1] , have now been classified in the most recent 2016 WHO Classification into a standby catch all category, ''CNS Embryonal Tumor, not otherwise specified" (CNS embryonal tumor, NOS) based on epigenetic, biologic and histopathologic criteria [2] [3] [4] [5] [6] .
The optimal treatment for CNS embryonal tumors (NOS), which are aggressive tumors, remains unknown. Historically, due to their histologic similarity to medulloblastoma, children with these tumors were treated with protocols designed for high-risk medulloblastoma, including upfront surgery followed by cranio-spinal irradiation (CSI) as well as platinum and alkylator-based chemotherapy [7, 8] . This intensive chemo-radiation approach was also adopted for the treatment of adults with this disease, and remains the mainstay of therapy [9] . This is despite the acceptance that medulloblastoma and CNS embryonal tumors (NOS) are molecularly and genetically distinct [10] [11] [12] , with different treatment outcomes associated not only with the different tumor types, but also age groups [13] [14] [15] . The latter may be due to biologic tumor heterogeneity, but is also likely to be influenced by a poorer tolerance of high dose chemotherapies in adults. It is hoped that therapy tailored to exploit tumor biology may reduce treatment burden and improve the prognosis for this disease, which currently stands at less than 50% survival five years from diagnosis in children, and is even lower in adults [15] . Here we describe the case of an adult female whose treatment would have been significantly altered with an improved understanding of the biology of her tumor.
Materials and methods

Informed consent
Consent was obtained from the patient on whom this case report was based.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on formalin-fixed paraffin embedded tissue using the Roche Ventana Ultra platform (Roche Diagnostics, North Ryde, Australia). For ATRX detection, a rabbit polyclonal antibody (1:200 dilution) (Sigma-Aldrich, Castle Hill, Australia) was used with platform conditions: 92 min in cell conditioning solution at 95°C, 120 min incubation with primary antibody at 36°C, UV amplification for signal detection. For IDH1 detection, a H09 clone monoclonal antibody (1:100 dilution) (Dianova, Hamburg, Germany) was used with platform conditions: 64 min in cell conditioning solution at 95°C, 28 min incubation with primary antibody at 36°C, UV amplification for signal detection.
Methylation analysis
DNA methylation levels were quantified using the Illumina Infinium HumanMethylation450 array (450 k array, Illumina, San Diego, CA, USA) as previously described [16] . For comparison, 50 reference samples of different GBM subgroups were selected from a previously published cohort [17] . MGMT promoter methylation status was determined as previously described [18] .
DNA sequencing
Sanger DNA sequencing of IDH1 exon 4 and IDH2 exon 4 was carried out on PCR amplified DNA extracted from formalin-fixed paraffin embedded tumor tissues. PCRs containing primers IDH1
and IDH2(R) 5 0 -CTAGGCGAGGAGCTCCAGT-3 0 and 1.5 mM MgCl 2 were performed with an annealing temperature of 57°C using a BioRad C1000 thermal cycler (BioRad, Gladesville, Australia). DNA sequences were compared to NCBI reference sequences IDH1: NG_023319.2 and IDH2: NG_023302.1.
Results
Case report
In 2013, a previously healthy 45-year old woman presented with a four-week history of headaches, short-term memory loss and personality change. She underwent an MRI scan of her brain and spine, which revealed an 82 mm irregular rim-enhancing solid-cystic mass, involving both frontal lobes [ Fig. 1A ]. Meningeal enhancement was also seen extending posteriorly to the hypothalamus. Due to clinical signs and symptoms consistent with raised intracranial pressure she underwent urgent maximal debulking surgery, with post-operative scans demonstrating near-total resection. Histopathological examination of the resection specimen showed a cellular neoplasm composed of poorly differentiated cells arranged in irregular aggregates and cords with spread to the leptomeninges and the Virchow-Robin spaces but notably not invading the cortex and white matter. The IDH1(R132H) immunohistochemical stain was not performed in view of the morphological appearance of the tumor and the ATRX immunohistochemical stain was not available at the time of receipt of the original resection specimen. The histological findings were considered to be most consistent with CNS-PNET, WHO grade IV, now known as a CNS embryonal tumor (NOS) [6] .
The patient underwent treatment with CSI (35 Gy with a 16 Gy boost to the tumor bed) and weekly vincristine. An MRI scan six weeks after completion of radiotherapy confirmed stable disease, and the patient went on to receive six of a planned eight cycles of platinum and alkylator-based chemotherapy. This initially consisted of cisplatin, vincristine and cyclophosphamide, although after the third cycle carboplatin was substituted for cisplatin due to grade 3 ototoxicity. Treatment was terminated early after the patient developed grade 3 peripheral neuropathy, and a further MRI scan at that time again showed stable disease.
The patient remained well for the next four months, but represented thirteen months from diagnosis with increasing fatigue, vagueness, weakness and ataxia. MRI at this point showed multiple new areas of leptomeningeal enhancement involving the brain stem, cerebellum and spinal cord, with cerebro-spinal fluid analysis revealing a markedly raised protein of 3.05 g/L, although malignant cells were not detected. An Ommaya reservoir was inserted and she received twice-weekly intrathecal methotrexate therapy for four weeks, and then weekly thereafter. Serial CSF analysis showed consistent reduction in protein levels to a minimum of 0.45 g/L, and an improvement in the patient's presenting symptoms. However, she quickly went on to develop progressive radic- ular pain, and a further MRI was performed. Although this showed improvement in most areas of disease, progressive disease was evident, including a lesion at T11 that explained the new symptomatology.
Intrathecal methotrexate therapy was ceased at this point and genomic analysis of the patient's original tumor tissue was undertaken using the Illumina 450 k array to help guide ongoing therapy. In the interim, the patient commenced intravenous irinotecan and oral temozolomide, which markedly improved her radicular pain. The DNA methylation array data revealed that the tumor had characteristics similar to IDH-mutant astrocytomas [ Fig. 1F] , and displayed MGMT promoter methylation as assessed according to the MGMT-STP27 model of Bady et al. [Fig. 1G] [18] . The presence of an IDH1 (R132H) mutation was subsequently confirmed by IHC (data not shown) and gene sequencing [ Fig. 1H] . The tumor cells also showed loss of nuclear staining for ATRX [ Fig. 1I ], indicating an ATRX mutation. Further IHC performed in 2015 following receipt of the results of the molecular testing showed positive staining for IDH1(R132H) and absence of nuclear staining for ATRX in the tumor cells. As a result, the tumor was re-classified according to the 2007 WHO criteria as a high-grade small cell astrocytoma [19] . According to the revised 4th edition of the WHO Classification of Tumors of the Central Nervous System [6] , the tumor would be classified as an anaplastic astrocytoma, IDHmutant, ATRX mutant. Temozolomide was continued as a single agent for a further two cycles. Upon completion of these cycles, MRI showed a complete radiologic response in all areas of previous disease, but a new mass was identified in the right frontal lobe with significant surrounding edema. This mass was FDG-PET avid, and the patient quickly became symptomatic with increasing vagueness, weakness, falls and incontinence. The patient underwent a further resection to ameliorate her symptoms. Histopathologic examination of this specimen showed extensive necrosis with only small numbers of IDH1 (R132H)-positive astrocytes, consistent with extensive therapy-related changes. After a period of rehabilitation, her condition significantly improved and she was recommenced on temozolomide, with subsequent stability in her clinical status for a period of four months. However, four months later, just over two years from original diagnosis, MRI showed further progression in the posterior aspect of the right frontal lobe. Clinically well, the patient was then commenced on bevacizumab leading to a complete radiological response. After 4 months, a subsequent MRI showed ongoing response in the frontal lobe, but leptomeningeal progression in the right temporal lobe. Lomustine was added to the bevacizumab and another response followed by stable disease was achieved for a further 6 months. At this time, although there was no significant disease progression, the patient's clinical status deteriorated and she was transitioned to palliative care and passed away 3 months later, 3 years since her original diagnosis.
Discussion
This case highlights the inadequacy of histology alone for the diagnosis of brain tumors, an issue that has challenged the field for decades. It is only relatively recently that this situation has begun to improve concomitant with significant advances in understanding the elusive underlying molecular complexity, particularly of pediatric brain tumors. With regard to CNS embryonal tumors (NOS), varying frequencies of gene mutations, deletions and amplifications have been reported in the literature [20] [21] [22] [23] [24] [25] [26] [27] , but it is only recently through integrative genomic analyses and DNA methylation profiling that evidence has emerged supporting the concept that distinct genetic subgroups exist within this tumor entity [2,3,5].
Sturm et al. undertook the most extensive molecular profiling study of ''CNS-PNETs" so far, involving 323 institutionally diagnosed tumors, including 36 tumors from adult patients (>18 years old) [5] . The analysis revealed that 61% of ''CNS-PNETs" represented morphological variants of other brain tumor types, including predominantly pHGG (31%) and ETMR (11%). Importantly, 24% of the remaining tumors were redefined into four new molecular entities, CNS NB-FOXR2, CNS EFT-CIC, CNS HGNET-MN1, and CNS HGNET-BCOR, and a further 15% did not cluster with any other known CNS tumor subgroup [5] .
The study of Sturm and colleagues confirmed that adult CNS embryonal tumors (NOS), like their childhood counterparts, display significant molecular heterogeneity, and often resemble other known brain tumor entities. With this in mind, and in order to inform our ongoing relapse treatment strategy more adequately, we decided to undertake methylation profiling of our patient's diagnostic tumor sample with the Illumina 450 k array. This revealed that despite the patient's tumor displaying histopathologic features consistent with a CNS embryonal tumor (NOS) by WHO criteria, it was in fact more appropriately classified as an IDH-mutant astrocytoma. Consistent with this, of the four HGG subtypes identified by Sturm et al., HGG with IDH1 mutation (HGG IDH ) was the only subtype predominantly associated with adults. In gliomas, the status of molecular biomarkers, including mutant IDH1, 1p/19q co-deletion, TERT or MGMT promoter methylation and ATRX mutation, refine prognosis and inform likely response to treatment [28] [29] [30] [31] [32] . The combination of IDH1 mutation with ATRX loss and MGMT methylation seen in our patient suggested that the tumor fell into a subgroup of astrocytomas with a better prognosis than typical glioblastoma, and the patient would likely benefit from therapy with temozolomide [32] . We used this information to tailor our patient's treatment, avoiding further intravenous chemotherapies and the associated toxicities.
As alluded to above, it is becoming increasingly clear that the current histopathologic classification system and standardized treatment fails to adequately address the biologic diversity of CNS embryonal tumors (NOS). Our case highlights the need to develop a combined diagnostic approach based on clinical and histopathological features, which also incorporates molecular findings such as global DNA methylation patterns, copy number alterations and additional genetic analyses to more accurately distinguish brain tumor subtypes [4] . This would allow development of a stratification system across the entire age spectrum, classifying tumors into subgroups with differing clinical implications, and enabling the development of novel subgroupspecific therapies.
Although we acknowledge that molecular classification using the 450 k methylation array remains experimental and is not widely available at present, we propose that consideration should be given to applying this approach, or at least IDH1 mutation testing and ATRX IHC, for any adult diagnosed with a CNS embryonal tumor (NOS), to improve diagnostic accuracy given the significant prognostic and therapeutic implications exemplified in our case. 
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